Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report

Jessica D St Laurent; Mary Kathryn Abel; Joyce Liu; Bradley J Quade; Michelle R Davis

doi:10.1016/j.gore.2024.101322

Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report

Gynecol Oncol Rep. 2024 Jan 3:51:101322. doi: 10.1016/j.gore.2024.101322. eCollection 2024 Feb.

Authors

Jessica D St Laurent¹, Mary Kathryn Abel¹, Joyce Liu², Bradley J Quade³, Michelle R Davis¹

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA, USA.
³ Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

•Ovarian carcinosarcoma is a rare ovarian cancer histology that has limited treatment options.•In this study, we present an unusual association between carcinosarcoma and a STIC lesion.•In select patients with carcinosarcoma, PARP inhibition may provide clinical benefit.

Keywords: Carcinosarcoma; Ovarian carcinoma; STIC.

Publication types

Case Reports